Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Regulation of KIR3DL3 Expression via Mirna.

Nutalai R, Gaudieri S, Jumnainsong A, Leelayuwat C.

Genes (Basel). 2019 Aug 9;10(8). pii: E603. doi: 10.3390/genes10080603.

2.

Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome.

Lucas M, Deshpande P, James I, Rauch A, Pfafferott K, Gaylard E, Merani S, Plauzolles A, Lucas A, McDonnell W, Kalams S, Pilkinton M, Chastain C, Barnett L, Prosser A, Mallal S, Fitzmaurice K, Drummer H, Ansari MA, Pedergnana V, Barnes E, John M, Kelleher D, Klenerman P, Gaudieri S.

Sci Rep. 2018 May 8;8(1):7224. doi: 10.1038/s41598-018-25559-6.

3.

Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.

Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE.

J Virol. 2018 Apr 13;92(9). pii: e02066-17. doi: 10.1128/JVI.02066-17. Print 2018 May 1.

4.

Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects.

Abana CO, Pilkinton MA, Gaudieri S, Chopra A, McDonnell WJ, Wanjalla C, Barnett L, Gangula R, Hager C, Jung DK, Engelhardt BG, Jagasia MH, Klenerman P, Phillips EJ, Koelle DM, Kalams SA, Mallal SA.

J Immunol. 2017 Nov 1;199(9):3187-3201. doi: 10.4049/jimmunol.1700851. Epub 2017 Oct 2.

5.

Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia.

Styles CE, Seed CR, Hoad VC, Gaudieri S, Keller AJ.

Vox Sang. 2017 Nov;112(8):723-732. doi: 10.1111/vox.12597. Epub 2017 Sep 27.

PMID:
28960337
6.

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ.

Sci Rep. 2017 Aug 17;7(1):8653. doi: 10.1038/s41598-017-08876-0.

7.

Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Karnes JH, Shaffer CM, Cronin R, Bastarache L, Gaudieri S, James I, Pavlos R, Steiner HE, Mosley JD, Mallal S, Denny JC, Phillips EJ, Roden DM.

Pharmacotherapy. 2017 Sep;37(9):1164-1171. doi: 10.1002/phar.1983. Epub 2017 Sep 4.

8.

Influence of Transmitted Virus on the Host's Immune Response: A Case Study.

Merani S, Lucas M, Deshpande P, Pfafferott K, Chopra A, Cooper D, Leary S, Luciani F, Gaudieri S.

Viral Immunol. 2017 Sep;30(7):533-541. doi: 10.1089/vim.2017.0001. Epub 2017 May 22.

PMID:
28530508
9.

Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants.

Karnes JH, Bastarache L, Shaffer CM, Gaudieri S, Xu Y, Glazer AM, Mosley JD, Zhao S, Raychaudhuri S, Mallal S, Ye Z, Mayer JG, Brilliant MH, Hebbring SJ, Roden DM, Phillips EJ, Denny JC.

Sci Transl Med. 2017 May 10;9(389). pii: eaai8708. doi: 10.1126/scitranslmed.aai8708.

10.

Innate and adaptive immunity shape circulating HCV strains.

Gaudieri S, Lucas M.

Nat Genet. 2017 Apr 26;49(5):657-658. doi: 10.1038/ng.3856.

PMID:
28442794
11.

Comparison of HLA allelic imputation programs.

Karnes JH, Shaffer CM, Bastarache L, Gaudieri S, Glazer AM, Steiner HE, Mosley JD, Mallal S, Denny JC, Phillips EJ, Roden DM.

PLoS One. 2017 Feb 16;12(2):e0172444. doi: 10.1371/journal.pone.0172444. eCollection 2017.

12.

HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.

Magaret A, Dong L, John M, Mallal SA, James I, Warren T, Gaudieri S, Koelle DM, Wald A.

Genes Immun. 2016 Dec;17(7):412-418. doi: 10.1038/gene.2016.42. Epub 2016 Nov 17.

13.

Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.

Barnard R, Chopra A, James I, Blinco J, Watson MW, Jabara CB, Hazuda D, Lemon SM, Mallal S, Gaudieri S.

Antivir Ther. 2016;21(7):567-577. doi: 10.3851/IMP3056. Epub 2016 May 24.

PMID:
27219495
14.

Longitudinal Trends in Western Australian HIV-1 Sequence Diversity and Viral Transmission Networks and Their Influence on Clinical Parameters: 2000-2014.

Castley AS, Gaudieri S, James I, Gizzarelli LS, Guelfi G, John M, Nolan D.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):211-9. doi: 10.1089/AID.2015.0206. Epub 2015 Dec 1.

PMID:
26530340
15.

Helicobacter pylori adaptation in vivo in response to a high-salt diet.

Loh JT, Gaddy JA, Algood HM, Gaudieri S, Mallal S, Cover TL.

Infect Immun. 2015 Dec;83(12):4871-83. doi: 10.1128/IAI.00918-15. Epub 2015 Oct 5.

16.

Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.

Pfafferott K, Deshpande P, McKinnon E, Merani S, Lucas A, Heckerman D, Mallal S, John M, Gaudieri S, Lucas M.

PLoS One. 2015 Jun 24;10(6):e0130420. doi: 10.1371/journal.pone.0130420. eCollection 2015.

17.

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.

von Delft A, Humphreys IS, Brown A, Pfafferott K, Lucas M, Klenerman P, Lauer GM, Cox AL, Gaudieri S, Barnes E.

Gut. 2016 Jan;65(1):112-23. doi: 10.1136/gutjnl-2014-308724. Epub 2015 Jun 19.

18.

Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 - a case control study.

Strock SB, Gaudieri S, Mallal S, Yu C, Mitchell D, Cogan J, Mason W, Crowe D, Loyd JE.

BMC Infect Dis. 2015 May 5;15:206. doi: 10.1186/s12879-015-0943-7.

19.

Influence of host resistance on viral adaptation: hepatitis C virus as a case study.

Plauzolles A, Lucas M, Gaudieri S.

Infect Drug Resist. 2015 Apr 7;8:63-74. doi: 10.2147/IDR.S49891. eCollection 2015. Review.

20.

Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.

Bull RA, Leung P, Gaudieri S, Deshpande P, Cameron B, Walker M, Chopra A, Lloyd AR, Luciani F.

J Virol. 2015 May;89(10):5478-90. doi: 10.1128/JVI.03717-14. Epub 2015 Mar 4.

21.

Abacavir-reactive memory T cells are present in drug naïve individuals.

Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, Moran EM, Meyer-Pannwitt V, Gaudieri S, D'Orsogna L, Kalams S, Ostrov DA, Buus S, Peters B, Mallal S, Phillips E.

PLoS One. 2015 Feb 12;10(2):e0117160. doi: 10.1371/journal.pone.0117160. eCollection 2015.

22.

New hope for biomarkers in the practice of infectious diseases medicine.

White K, Gaudieri S.

Biomark Med. 2014;8(9):1049-51. doi: 10.2217/bmm.14.94. No abstract available.

23.

Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines.

John M, Gaudieri S.

Front Microbiol. 2014 Oct 13;5:514. doi: 10.3389/fmicb.2014.00514. eCollection 2014. Review.

24.

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV.

Antivir Ther. 2015;20(2):199-208. doi: 10.3851/IMP2821. Epub 2014 Aug 8.

25.

HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.

Nitschke K, Barriga A, Schmidt J, Timm J, Viazov S, Kuntzen T, Kim AY, Lauer GM, Allen TM, Gaudieri S, Rauch A, Lange CM, Sarrazin C, Eiermann T, Sidney J, Sette A, Thimme R, López D, Neumann-Haefelin C.

J Hepatol. 2014 Jan;60(1):22-9. doi: 10.1016/j.jhep.2013.08.009. Epub 2013 Aug 23.

26.

The role of biomarkers in the prevention of globally important diseases.

Lucas M, Gaudieri S.

Biomark Med. 2013 Jun;7(3):331-2. doi: 10.2217/bmm.13.54. No abstract available.

27.

Hepatitis C virus adaptation to T-cell immune pressure.

Plauzolles A, Lucas M, Gaudieri S.

ScientificWorldJournal. 2013;2013:673240. doi: 10.1155/2013/673240. Epub 2013 Mar 11. Review.

28.

The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.

Herrmann S, Wardrop J, John M, Gaudieri S, Lucas M, Mallal S, Nolan D.

Sex Health. 2012 Nov;9(5):407-13. doi: 10.1071/SH11181.

PMID:
22950904
29.

IFN-λ and IgE-mediated allergic disease: a potential future role?

Gaudieri S, Tulic MK, Lucas A, Lucas M.

Biomark Med. 2012 Apr;6(2):151-7. doi: 10.2217/BMM.12.12. Review.

PMID:
22448789
30.

The interferon family as biomarkers of disease: renaissance of the innate immune system.

Lucas M, Gaudieri S.

Biomark Med. 2012 Apr;6(2):133-5. doi: 10.2217/BMM.12.15. Review. No abstract available.

31.

Genetic variations in IL28B and allergic disease in children.

Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A, di Iulio J, Martino D, Prescott SL, Tulic MK.

PLoS One. 2012;7(1):e30607. doi: 10.1371/journal.pone.0030607. Epub 2012 Jan 25.

32.

Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease.

Desmond CP, Gaudieri S, James IR, Pfafferott K, Chopra A, Lau GK, Audsley J, Day C, Chivers S, Gordon A, Revill PA, Bowden S, Ayres A, Desmond PV, Thompson AJ, Roberts SK, Locarnini SA, Mallal SA, Lewin SR.

J Virol. 2012 Jan;86(2):1181-92. doi: 10.1128/JVI.05308-11. Epub 2011 Nov 9.

33.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC).

PLoS Med. 2011 Sep;8(9):e1001092. doi: 10.1371/journal.pmed.1001092. Epub 2011 Sep 13.

34.

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.

Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA, Lloyd AR.

PLoS Pathog. 2011 Sep;7(9):e1002243. doi: 10.1371/journal.ppat.1002243. Epub 2011 Sep 1.

35.

Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.

Dong T, Zhang Y, Xu KY, Yan H, James I, Peng Y, Blais ME, Gaudieri S, Chen X, Lun W, Wu H, Qu WY, Rostron T, Li N, Mao Y, Mallal S, Xu X, McMichael A, John M, Rowland-Jones SL.

Blood. 2011 Jul 7;118(1):98-106. doi: 10.1182/blood-2010-06-291963. Epub 2011 May 11.

36.

Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection.

Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, McKiernan S, Norris S, Long A, Kelleher D, Klenerman P.

Gut. 2011 Nov;60(11):1563-71. doi: 10.1136/gut.2010.228403. Epub 2011 May 6.

37.

Biomarkers that reflect immune activation or dysfunction will be important in the management of infectious diseases.

Gaudieri S.

Biomark Med. 2011 Apr;5(2):109-12. doi: 10.2217/bmm.11.22. No abstract available.

38.

Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity.

Pfafferott K, Gaudieri S, Ulsenheimer A, James I, Heeg M, Nolan D, John M, Rauch A, Mallal S, Lucas A, Klenerman P, Diepolder HM, Lucas M.

PLoS One. 2011 Feb 8;6(2):e16797. doi: 10.1371/journal.pone.0016797.

39.

Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak.

Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, Rauch A, di Iulio J, John M, Lucas M, Fitzmaurice K, McKiernan S, Norris S, Kelleher D, Klenerman P, Gaudieri S.

Hepatology. 2011 Feb;53(2):396-405. doi: 10.1002/hep.24076. Epub 2011 Jan 18.

40.

Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins.

Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, Huang JC, Riadi G, Mallal S, Jojic N.

J Virol. 2011 Feb;85(3):1310-21. doi: 10.1128/JVI.01966-10. Epub 2010 Nov 17.

41.

Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.

Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, Telenti A, Keiser O, Günthard HF, Hirschel B, Hoffmann M, Bernasconi E, Battegay M, Furrer H, Klenerman P, Rauch A; Swiss HIV Cohort Study.

Gut. 2010 Sep;59(9):1252-8. doi: 10.1136/gut.2009.205971. Epub 2010 Jul 26.

42.

Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs.

John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D, Haas DW, Riddler SA, Haubrich R, Mallal S.

J Immunol. 2010 Apr 15;184(8):4368-77. doi: 10.4049/jimmunol.0903745. Epub 2010 Mar 15.

43.

Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.

Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ.

PLoS Pathog. 2009 Dec;5(12):e1000707. doi: 10.1371/journal.ppat.1000707. Epub 2009 Dec 24. Erratum in: PLoS Pathog. 2012 Jun;8(6). doi:10.1371/annotation/523d94fe-9730-499b-95b1-addd94089ff8.

44.

Host genetic determinants of spontaneous hepatitis C clearance.

Rauch A, Gaudieri S, Thio C, Bochud PY.

Pharmacogenomics. 2009 Nov;10(11):1819-37. doi: 10.2217/pgs.09.121. Review.

PMID:
19891557
45.

Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.

Humphreys I, Fleming V, Fabris P, Parker J, Schulenberg B, Brown A, Demetriou C, Gaudieri S, Pfafferott K, Lucas M, Collier J, Huang KH, Pybus OG, Klenerman P, Barnes E.

J Virol. 2009 Nov;83(22):11456-66. doi: 10.1128/JVI.00884-09. Epub 2009 Sep 9. Erratum in: J Virol. 2010 Feb;84(3):1664.

46.

Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.

Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Günthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S.

Hepatology. 2009 Oct;50(4):1017-29. doi: 10.1002/hep.23101.

PMID:
19670417
47.

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Günthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M.

Hepatology. 2009 Apr;49(4):1069-82. doi: 10.1002/hep.22773.

PMID:
19263475
48.

Missingness in the T1DGC MHC fine-mapping SNP data: association with HLA genotype and potential influence on genetic association studies.

James I, McKinnon E, Gaudieri S, Morahan G; Diabetes Genetics Consortium.

Diabetes Obes Metab. 2009 Feb;11 Suppl 1:101-7. doi: 10.1111/j.1463-1326.2008.01010.x.

49.

Forensic STRs as potential disease markers: a study of VWA and von Willebrand's Disease.

Laird R, Schneider PM, Gaudieri S.

Forensic Sci Int Genet. 2007 Dec;1(3-4):253-61. doi: 10.1016/j.fsigen.2007.06.002. Epub 2007 Jul 13.

PMID:
19083770
50.

Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study.

Rauch A, Gaudieri S, Evison J, Nolan D, Cavassini M, Weber R, James I, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(3):455-60.

PMID:
18572759

Supplemental Content

Loading ...
Support Center